Monitoring immune-checkpoint blockade: response evaluation and biomarker development. - Wikidata - awgldk - TriplyDB

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

http://www.wikidata.org/entity/Q38666241

about

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance.High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.B cells as biomarkers: predicting immune checkpoint therapy adverse events.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Trial watch: Immune checkpoint blockers for cancer therapy.Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance.Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases.The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.IL-2 and Beyond in Cancer Immunotherapy.Improving immune-vascular crosstalk for cancer immunotherapy.PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.Aptamer Therapeutics in Cancer: Current and Future.Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.CD103+ cells at the forefront of anticancer immunity.Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Key questions about the checkpoint blockade-are microRNAs an answer?Do immune checkpoint inhibitors need new studies methodology?A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease.New advances in immunotherapy for non-small cell lung cancer CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients Immunological-based approaches for cancer therapy Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics Biomarkers for Immune Checkpoint Inhibitors in Melanoma Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity

P2860

Q41538262-2DC30476-8792-4C87-A22B-EABD3E83BB3A Q46971015-C37A30DB-ECBB-4621-AD63-9755B6DFB9AB Q47109363-F725CE36-254B-4878-8A2D-23109829C239 Q47124504-EFACD24F-FAD8-4EB1-AC76-EB667BE182AE Q47225234-E35D587C-E903-407A-A735-CD75CF2201F6 Q47225274-5611D63B-898B-4BB7-9978-28BA821B0C64 Q47325431-DB43E833-2B63-4DD4-9B5D-AA06A3F4BD1E Q47393365-837B6660-F5CC-4D17-A781-DBA8B6DECB8E Q47551609-C12B5F4B-BBA4-4E93-86F7-1469E793E275 Q47564468-C8FBDBF0-814F-401A-A383-76DF9B01262E Q47655604-D15DAB63-1482-4FD8-8270-03BA4B466686 Q48156081-5CA7AE35-9115-467F-B999-A34FEA6C04D0 Q49887884-33693425-2898-4E79-82D8-9A6CEFBEA25F Q50004232-9CEE99CE-38BA-466D-8F9A-4CE564285932 Q50051034-63889CF5-C8E4-40D5-9011-1BF46084D205 Q50054711-A1AB6FD6-5A7D-4982-80E2-C7A3D1ED0952 Q50070316-C8B10A3D-E063-498A-AF54-0CB54799B783 Q50083199-A9751807-502F-430B-BD37-7889C76F950B Q52347485-B71B68EF-6E78-4D2A-B8A9-1919F3BFA9BF Q52583527-DE856C6C-8271-47DD-933E-F389584F770C Q52621246-8034CACC-BB5C-42EF-ADC7-0856584823E0 Q52657150-87A9F07C-9A2C-43D1-B7C2-37869DAF5F65 Q52718113-2C77862F-A348-4AEA-A9FE-5DD399CEDE31 Q52743918-96A6BA19-E13D-4AF9-8946-9D23A7996135 Q52780158-525C8017-310E-4ED6-9F67-0219C3213B60 Q55079562-DC983DC9-136B-4452-AC58-DF10968E85E3 Q55093553-25C84239-6354-4C7D-A5AE-6B5C0D11D3D7 Q55114350-5216D9B7-C785-4738-886C-5E0218088F91 Q55190117-F1519775-C1A2-4AE2-A1BF-F56C805D1890 Q55287125-E306DC9F-8BCD-4666-A33A-9714C79C6219 Q55339993-B56D0A82-2EA9-46F6-9191-00E009D7B937 Q55375458-6678EBF0-CA87-4581-A7F2-9C9D5A051C9F Q55456412-478D8BF4-FA94-4E20-B788-6F9F609C5A8C Q56890070-CCD58021-6448-409C-8355-9C575286D71B Q56891027-3CC961B4-DFB2-4643-B57A-2B92575F896D Q57168423-34449956-9182-4BFE-94AF-58901D98F590 Q57169731-94A000D0-3DDD-499D-AA34-0A6D248295D2 Q57175477-E67245D9-0E58-4B7B-9421-F86EA72A6629 Q57191808-03C1B410-9C65-41CB-9938-D77926FAF832 Q57491420-3B2065C3-25C6-43AB-B97A-8AD2E6337D81

P2860

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

http://www.wikidata.org/entity/Q38666241

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

@en

type

label

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

@en

prefLabel

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

@en

P1433

Q38666241-1AE314F8-8F19-49C8-BC31-74859B1924B1

P1476

Q38666241-02E74CD8-C958-40A5-9EF2-D0A118D19566

P2093

Q38666241-AF02A44A-D928-4F5A-8349-7097233BF9C1

Q38666241-C243CBED-0CDE-43AA-9042-A002001404C8

Q38666241-DA68FE3D-24AA-4B3E-BD88-802CB25E3194

Q38666241-F9B8CB74-1C48-4DD6-ACA3-4DF2DC860A67

P2860

Q38666241-00B04C2D-B4DB-4EB7-AF3E-062BB9E94638

Q38666241-0187E840-EDC9-427D-A3AF-B0ABAA273DB1

Q38666241-01892920-E394-485E-960E-3437B036FD1E

Q38666241-0351AC9F-503B-40DF-B73C-6A00AE2ACC53

Q38666241-04141C0E-B828-46A9-90AF-3BF821538868

Q38666241-05D2D891-7445-411D-8AB8-C35915212F8A

Q38666241-065E52E0-1B2B-4192-B602-B02069519686

Q38666241-077E92FE-0EDD-413B-8187-B42FB725AB0E

Q38666241-09B0A0E0-50A4-4FA6-A79F-D0CA66AE0966

Q38666241-09F39CCB-BDDE-4F43-B714-06FE34C3EAAE

P2888

Q38666241-F45F33AE-EB95-41BE-9116-F4F89F846B79

P31

Q38666241-64755790-CCCA-415D-B056-15DF00B7AA00

P356

Q38666241-1F515052-25C3-49B6-A6E9-C8A14F148E19

P407

Q38666241-403991B7-F92C-4E98-B518-9A1EFDD1B17B

P577

Q38666241-C4A756CC-0C81-4C1C-A0A6-FC531BE0BDD8

P6179

Q38666241-1B0A68AB-B14D-4ABB-8E96-7051067D6E05

P698

Q38666241-8EC883BE-9B11-4954-948B-B4FB981D8513

P921

Q38666241-68820B1C-CBFC-49A1-A089-CA1124921ED1

P932

Q38666241-43F123FC-0E22-4F88-AAC3-AF45283B1218

P356

NRCLINONC.2017.88

P1433

Nature Reviews Clinical Oncology

P1476

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

@en

P2093

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Hiroto Hatabu

http://www.w3.org/2001/XMLSchema#string

Mizuki Nishino

http://www.w3.org/2001/XMLSchema#string

Nikhil H Ramaiya

http://www.w3.org/2001/XMLSchema#string

P2860

CD28/B7 system of T cell costimulation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

P2888

nrclinonc.2017.88

P31

scholarly article

P356

10.1038/NRCLINONC.2017.88

http://www.w3.org/2001/XMLSchema#string

P407

P577

2017-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086289497

http://www.w3.org/2001/XMLSchema#string

P698

28653677

http://www.w3.org/2001/XMLSchema#string

P921

P932

5650537

http://www.w3.org/2001/XMLSchema#string